Clinical Trial Update: Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ACP-196 (calquentinib) in combination with pembrolizumab for metastatic urothelial carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• ACP-196 (acalabrutinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Metastatic Urothelial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-09-10